R
Read Gene SA
WSE:RDG
Read Gene SA
WSE:RDG
Price:
5.44
PLN
2.64%
Market Closed
Market Cap:
zł64.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Read Gene SA
Accounts Payable
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Read Gene SA
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Read Gene SA
WSE:RDG
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Accounts Payable
zł2m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-18%
|
|
|
G
|
Genomed SA
WSE:GEN
|
Accounts Payable
zł481.4k
|
CAGR 3-Years
6%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-3%
|
|
|
B
|
Bioton SA
WSE:BIO
|
Accounts Payable
zł17.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-16%
|
|
|
U
|
Urteste SA
WSE:URT
|
Accounts Payable
zł1.3m
|
CAGR 3-Years
72%
|
CAGR 5-Years
101%
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Accounts Payable
zł11.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Read Gene SA
Glance View
Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.
RDG
Intrinsic Value
2.93
PLN
Overvaluation 46%
R
